Edinburgh, United Kingdom
Edinburgh, United Kingdom

Time filter

Source Type

News Article | April 19, 2017
Site: tech.eu

Scottish Synpromics Ltd, a gene control company, has raised £5.2 million. The funding comes from existing investors Calculus Capital, the Scottish Investment Bank, the investment arm of Scottish Enterprise, and private shareholders. Synpromics develops synthetic promoters - DNA sequences that do not exist in nature, and are designed to regulate the activity of genes. Currently, the biotech industry relies mostly on naturally occurring promoters, however Synpromics has developed technology that allows for the design of synthetic promoters to customize gene regulation at the desired level of specificity. The company says its technology gives biological researchers, developers and manufacturers unprecedented control of gene expression through by creating a portfolio of man-made DNA regulatory sequences. The company says it will use the majority of the new investment to further develop its PromPT™ synthetic promoter design platform. PromPT™ enables the design of unique synthetic promoters which give precise control of gene function in many areas of gene medicine including gene therapy, cell therapy and gene editing. The company is also preparing to move into a larger facility. Synpromics has expanded over the past two years, attracting international customers including gene therapy companies and multinational technology corporations, most recently GE Healthcare. “Since our last fundraising round 18 months ago the business has grown rapidly as we’ve signed more commercial partnerships with companies in the US and Europe," said David Venables, CEO of Synpromics, in a statement. "We see an exciting opportunity to fund further rapid expansion of our business, supported by our innovative science and novel capabilities.” “We have been delighted with the progress which Synpromics has made since we made our first investment some 18 months ago," added Alexandra Lindsay, Investment Director at Calculus Capital. "They have a very strong team and the technology has been clearly validated through partnerships with some of the world’s leading gene medicine companies.”


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Feasibility Study | Award Amount: 241.60K | Year: 2013

Enhancing methods of protein expression is fundamentally important to new drug development and the efficient production of biopharmaceuticals. The consortium aims to develop a novel means of designing and constructing synthetic promoters that can be employed on an industrial scale to drive the expression of proteins for commercial applications. This will be achieved by combining the synthetic promoter design capabilities of Synpromics with improved DNA assemble methodology from Genabler and systems biology expertise from the SynthSYS institute of the University of Edinburgh. The project will yield a novel platform technology that can be used to create synthetic promoters with multiple applications across the biotech sector. This initial feasibility study will incorporate disparate expertise from the three partners to construct synthetic promoters that can enhance the production of proteins in mammalian cell culture systems, with a view to improve upon protein yield and quality.


Patent
Synpromics Ltd | Date: 2012-07-25

The present application relates to a system for designing promoters for selective expression of genes. Thereby identified transcription regulatory elements are selected according to a specific methodology and used to create a library of transcription regulatory elements, which are then used to construct specific promoters, especially tissue-specific promoters.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 1.58M | Year: 2016

Evolving therapeutic approaches of cell and gene therapy are harnessing the power of viruses in order to modify genomes of cells to produce a therapeutic effect. Such therapies are starting to show efficacy in the clinic, but one of the key challenges to their widespread use is the ability to make large quantities of virus at a low cost. This project seeks to address this challenge by creating new methods of producing large quantities of virus at a low cost. It brings together Synpromics, a synthetic biology company based in Edinburgh, and the Cell Therapy Catapult, one of the UK’s network of Catapult centres focused on developing and growing a cell and gene therapy industry in the UK.


Patent
Synpromics Ltd | Date: 2012-01-25

The present application relates to a system for designing promoters for selective expression of genes. Thereby identified transcription regulatory elements are selected according to a specific methodology and used to create a library of transcription regulatory elements, which are then used to construct specific promoters, especially tissue-specific promoters.


Trademark
Synpromics Ltd | Date: 2015-10-23

Biological materials including genetic constructs, especially synthetic promoters and vectors, namely, synthetic DNA that acts as a gene switch or promoter to control the activation of a target gene, by regulating its transcription into RNA and its translation into protein for industry, science and agricultural use; nucleic acids for laboratory use; materials for the construction of genetic constructs, especially synthetic promoters and vectors, namely, DNA that acts as a gene switch or promoter to control the activation of a target gene, by regulating its transcription into RNA and its translation into protein for industry, science and agricultural use; biological tissue, namely, cells for scientific, laboratory or medical research; viruses and other carriers including such genetic constructs, namely, DNA that acts as a gene switch or promoter to control the activation of a target gene, by regulating its transcription into RNA and its translation into protein for industry, science and agricultural use. Biological preparations for medical purposes, namely, DNA that acts as a gene switch or promoter to control the activation of a target gene, by regulating its transcription into RNA and its translation into protein for transplant purposes, detecting mutations, for use as implants which are comprised of living tissue, and also used for the treatment of cancer, where controlled expression of a specific protein is required to ameliorate a pathologic phenotype in a targeted manner; biological preparations for veterinary purposes, namely, DNA that acts as a gene switch or promoter to control the activation of a target gene, by regulating its transcription into RNA and its translation into protein for transplant purposes, detecting mutations, for use as implants which are comprised of living tissue, and also used for the treatment of cancer, where controlled expression of a specific protein is required to ameliorate a pathologic phenotype in a targeted manner. Agricultural, products, namely, agricultural seeds; aquacultural products, namely, aquaculture feed; horticultural products, namely, bulbs for horticultural purposes and seeds for horticultural purposes; seeds, namely, crop seeds and grass seeds; natural plants and flowers, where controlled expression of a specific protein is required to convey a selected advantage. Biotechnological research and biotechnological development services, namely, design of biological materials in the nature of genetic constructs, especially synthetic promoters and vectors, cells, viruses and carriers of genetic constructs with synthetic promoters and vectors; scientific research in the nature of analysis and profiling of gene expression; scientific research in the field of analysis and profiling of gene expression; and providing technical information services in relation to the aforesaid services. Medical services; veterinary services.


Trademark
Synpromics Ltd | Date: 2016-12-21

Biological materials including genetic constructs, especially synthetic promoters and vectors; nucleic acids; materials for the construction of genetic constructs, especially synthetic promoters and vectors; cells, viruses and other carriers including such genetic constructs. Biological preparations for medical purposes; biological preparations for veterinary purposes. Agricultural, aquacultural, horticultural and forestry products; seeds; natural plants and flowers; propagation material. Biotechnological research and development services, including: design and provision of biological materials including genetic constructs, especially synthetic promoters and vectors; cells, viruses and other carriers including such genetic constructs; analysis and profiling of gene expression; technical information services in relation to the aforesaid and in respect of the construction of genetic constructs, especially synthetic promoters and vectors.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 207.83K | Year: 2014

The collaboration between Synpromics Ltd. and Touchlight Genetics Ltd. will combine two highly innovative and complementary technology platforms to develop an improved approach to developing DNA vaccines. The project will leverage Synpromicss proprietary technology to rationally design synthetic promoters that drive cell-specific antigen expression and that enhance the effectiveness of Touchlight Genetics’s unique synthetic DNA vaccine cassette platform. The resulting new technology will subsequently be applied by Touchlight Genetics in the company’s internal DNA vaccine develoment programs, as well as be available for licensing by other developers. The project is expected to establish a unique UK-based synthetic biology capability for the production of safer and more effective DNA-based medicines.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 289.78K | Year: 2014

The collaboration between Synpromics and Ingenza is focused on developing proprietary protein production systems in engineered yeast strains that improve on currently available alternatives by incorporating novel synthetic promoter constructs rationally designed to drive optimal gene expression. The enabling technology that the project aims to deliver will address significant limitations faced by a wide range of bio-manufacturers using yeast-based expression, enabling the more efficient production of protein products and intermediary production enzymes. The combination of Synpromicss and Ingenzas innovative technologies and expertise is expected to validate a platform on which to build an even broader range of solutions to yeast-based expression challenges, thereby establishing in the UK a leading capability in synthetic biology and sustainable industrial bioprocessing.


PubMed | StemTek Therapeutics and Synpromics Ltd
Type: | Journal: Stem cells translational medicine | Year: 2016

SummaryTumor development and the generation of induced pluripotent stem cells are highly comparable processes with striking similarities. Cellular plasticity is inherent to tumor evolution, rendering cells that acquire a stem cell-like phenotype, for which Sox2 activation has proved instrumental for the plastic acquisition of stemness properties in tumor cells. Understanding the molecular mechanisms underlying both events might uncover novel approaches for the development of anticancer therapeutics and constitute model systems for understanding tumor generation and ensuring the biosafety of cell-based therapies.Defining the molecular drivers of cancer stem-like cells will provide avenues for the rational design of cancer treatment regimens aimed at cancer stem cells, which combined with conventional treatments targeting the bulk tumor cells, will provide novel therapies for cancer patients. Screening methods based on pluripotency transcriptional reporters would help to identify new drugs targeting cancer stem cells and cellular plasticity.

Loading Synpromics Ltd collaborators
Loading Synpromics Ltd collaborators